General Information of Drug (ID: DMQKR2W)

Drug Name
6-(2-Fluoro-benzenesulfonyl)-2H-pyridazin-3-one Drug Info
Synonyms 6-(2-Fluoro-benzenesulfonyl)-2H-pyridazin-3-one; CHEMBL198119; SCHEMBL6205793; BDBM16600; AEDNYZQZIZUZTP-UHFFFAOYSA-N; Phenyl-Substituted Sulfonylpyridazinone, 8f
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9943009
TTD Drug ID
DMQKR2W

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Aldose reductase (AKR1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epalrestat DM5OGK0 Diabetic neuropathy 8C0Z Approved [2]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [3]
Fidarestat DMZL1I8 Diabetic complication 5A2Y Phase 3 [4]
Ranirestat DMD5QRS Diabetic neuropathy 8C0Z Phase 3 [5]
CONTIGOSIDE B DMX9V8K Thrombosis DB61-GB90 Phase 2/3 [6]
BNV-222 DMYFQJL Diabetic neuropathy 8C0Z Phase 2/3 [5]
BNV-222 DMYFQJL Diabetic neuropathy 8C0Z Phase 2/3 [7]
LIDORESTAT DMA0RI9 Diabetic complication 5A2Y Phase 2 [8]
QR-333 DMKVIWM Diabetic neuropathy 8C0Z Phase 2 [9]
ADMVA DM819CO Diabetic complication 5A2Y Phase 2 [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aldose reductase (AKR1B1) TTFBNVI ALDR_HUMAN Inhibitor [1]

References

1 A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39.
2 Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001 Sep-Oct;15(5):241-4.
3 Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8.
4 Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001 Oct;24(10):1776-82.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
6 Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5.
7 ClinicalTrials.gov (NCT02332005) 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (DE-DPN). U.S. National Institutes of Health.
8 Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors ... J Med Chem. 2005 May 5;48(9):3141-52.
9 A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005 Sep-Oct;19(5):247-53.